Lansoprazole。更新其药理学性质和临床疗效的管理与酸有关的疾病。

文章的细节

引用

复制到剪贴板

Langtry HD, Wilde MI

Lansoprazole。更新其药理学性质和临床疗效的管理与酸有关的疾病。

药物。1997九月;54(3):473-500。

PubMed ID

9279507 (PubMed视图

]

摘要

兰索拉唑是一种质子泵抑制剂，可减少胃酸分泌。它已被证明在根除幽门螺杆菌的联合治疗方案中有效，并作为单一疗法来治愈和缓解胃或十二指肠溃疡和胃食管反流的症状。在初步愈合后，它可用于防止幽门螺杆菌不是溃疡主要原因的患者食道糜烂或消化性溃疡的复发，并用于减少Zollinger-Ellison综合征患者的基底酸输出。通常的剂量为15 ~ 60mg /天，尽管剂量<或= 180mg /天已用于高分泌状态的患者。在十二指肠溃疡或胃溃疡患者中，短期兰索拉唑单药治疗与奥美拉唑相似，且在治愈率> 90%方面优于组胺H2受体拮抗剂。在幽门螺杆菌根除方案中，兰索拉唑与奥美拉唑、双曲酸铋三钾(胶体次柠檬酸铋)或雷尼替丁一样有效。兰索拉唑在胃食管反流病的症状缓解和愈合方面优于雷尼替丁，且症状缓解快于奥美拉唑，但初始愈合相似。作为维持治疗，兰索拉唑在缓解症状和防止复发方面与奥美拉唑相似，优于雷尼替丁。在治疗与Barrett食管相关的食管糜烂症状方面，兰索拉唑也优于雷尼替丁;>或= 70%的患者平均维持了2.9年的愈合时间。 Lansoprazole was also superior to ranitidine in prophylaxis of redilatation of oesophageal strictures. After > or = 4 years of use in patients with Zollinger-Ellison syndrome, lansoprazole 60 to 180 mg/day effectively controlled basal acid output. Dosages may be reduced in some patients once healing and symptom relief has been achieved. Preliminary studies of lansoprazole in patients at risk of aspiration pneumonia or stress ulcers show promise. Although studies show lansoprazole is potentially effective in treating gastrointestinal bleeding, future studies should assess patients' H. pylori status. Lansoprazole has been well tolerated in clinical trials, with headache, diarrhoea, dizziness and nausea appearing to be the most common adverse effects. Tolerability of lansoprazole does not deteriorate with age and the drug is well tolerated in long term use (< or = 4 years) in patients with Zollinger-Ellison syndrome or reflux disease. Thus, lansoprazole is an important alternative to omeprazole and H2 receptor antagonists in acid-related disorders. In addition to its efficacy in healing or maintenance treatment, it may provide more effective symptom relief than other comparator agents.

引用本文的药物库数据

药物靶点

药物	目标	种类	生物	药理作用	行动
Lansoprazole	钾转运atp酶α链1	蛋白质	人类	是的	抑制剂	细节